Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes it a top stock to buy and hold for dividend investors -- arguably one of the better ones on the market. There are plenty of reasons to invest in the stock.
Abbott Laboratories (ABT) Gets a Buy from Wells Fargo
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report),
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
However, sales of these products started declining as the outbreak receded, leading to more uneven revenue growth for the company. Throughout it all, one of Abbott Laboratories' segments has been ...
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...
Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories ABT advanced 1.06% to $117.63 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.13% to 5,633.09 and the Dow Jones Industrial Average DJIA rising 0.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
Zacks.com on MSN2d
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...
pharmaphorum1d
A history of Abbott and AbbVie
"Abbott Laboratories began its 125th year with approximately ... "For our shareholders, we are developing the kind of essential, life-enhancing products that will ensure the enduring growth ...
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Fox Business16d
abbott laboratories
is questioning Abbott Laboratories' business practices after ... shortage that is leaving Americans scrambling to find the product.